Clomid, the brand name for clomiphene citrate, is not a steroid. It is a selective estrogen receptor modulator, a drug developed to induce ovulation in women, which men use off label to raise their own testosterone after a cycle suppresses it.
That off label use is widespread and rests on weaker evidence than most forum posts suggest. This guide separates what the label says, what the trials measured, and what remains unproven, with links to the sources used.
Key facts about Clomid
| Active substance | Clomiphene citrate |
| Drug class | Selective estrogen receptor modulator, nonsteroidal |
| Molecular formula | C26H28ClNO, molecular weight 406.0 |
| Tablet strength | 50 mg in the labelled product |
| Labelled use | Ovulatory dysfunction in women who want to conceive |
| Use in men | Off label, not covered by the label |
| Main risk to know | Visual symptoms, which rise with total dose and duration |
What clomiphene is
Clomiphene citrate is a nonsteroidal compound that binds estrogen receptors and blocks them. Its approved indication is narrow and specific: treatment of ovulatory dysfunction in women who want to become pregnant, after other causes of infertility have been excluded. The label lists the patients most likely to respond, including women with polycystic ovary syndrome and several forms of amenorrhea.
There is no approved indication for men. Everything written about Clomid in male use, including the numbers in this article, comes from clinical studies and review papers, not from the label.
How it raises testosterone
Testosterone production is controlled by a feedback loop. The hypothalamus and pituitary sense circulating estradiol and testosterone, and when levels are high enough they reduce the signals, luteinizing hormone and follicle stimulating hormone, that tell the testes to produce more.
Clomiphene blocks estrogen receptors in the hypothalamus, so the brain no longer reads the estrogen signal as strong. The brake comes off, luteinizing hormone and follicle stimulating hormone rise, and the testes are told to produce more testosterone. Because the testes are doing the work, sperm production is not shut down the way it is with injected testosterone, which is the whole reason this drug interests men who care about fertility.
This is why clomiphene is chosen by men who care about fertility, and why it does not work like a dose of testosterone.
What the trials show in men
The most useful recent summary is a 2026 systematic review and meta analysis comparing clomiphene with testosterone replacement therapy in male hypogonadism. It pooled 11 studies and 1512 patients, 764 on clomiphene and 748 on replacement therapy.
| Outcome | Result | How to read it |
|---|---|---|
| Serum testosterone, overall | No significant difference, mean difference 6.64 ng/dL, 95 percent CI -35.35 to 48.63 | Clomiphene can bring levels into a similar range as gel |
| Injectable testosterone subgroup | Injectable achieved higher levels than clomiphene, one study, 62 patients | Injections push levels harder than any oral SERM |
| Gel subgroup | No difference, 8 studies, 1012 patients | The largest comparison found parity |
| Libido | Replacement therapy gave greater improvement | Higher numbers do not automatically mean better symptoms |
| Certainty | High heterogeneity, I squared 80.6 percent, some risk of bias | The authors call the findings preliminary |
The authors state plainly that large randomised trials with clinical and fertility endpoints are still needed. That sentence is the honest summary of the whole field.
Heterogeneity was high at 80.6 percent and the authors call the findings preliminary. Injections did beat clomiphene in the one study that compared them.
Source: European Journal of Clinical Pharmacology, 2026, PMID 42435198
Clomid in post cycle therapy
After a course of exogenous androgens, the axis is suppressed and natural production is low. Post cycle therapy is the practice of using drugs to shorten that period. A 2026 narrative review on post cycle therapy describes the landscape accurately: SERMs such as clomiphene and tamoxifen, hCG and aromatase inhibitors are the usual agents, some studies suggest faster short term hormonal and seminal recovery, but spontaneous recovery happens in most people within months anyway, and the evidence base is weak.
The same review notes three positions that coexist: wide real world use, often without supervision, academic scepticism because benefits are uncertain and risks are real, and a pragmatic middle ground for selected people with heavy symptoms. If you are planning that phase, our guide to post cycle therapy walks through the mechanics and monitoring.
Dosing used in practice
There is no approved male dose, so anything below is a description of what studies and clinicians use, not a recommendation. The recovery range, including clomiphene, sits in cycle support.
| Setting | Typical pattern | Note |
|---|---|---|
| Labelled female use | 50 mg per day for 5 days, first course | The only dose written in the label |
| Male use in studies | 25 mg daily, or 50 mg every other day | Lower daily exposure, longer duration |
| Duration | 4 to 8 weeks, then reassessment | Judged by blood work, not by calendar |
Two practical points that follow from the label: visual symptoms increase with total dose and with duration, so raising the dose to speed things up is the wrong direction. And because the drug works through the brain rather than by adding hormone, the response is measured in luteinizing hormone, follicle stimulating hormone and total testosterone, not in how you feel in week one.
Side effects, including vision
The label is explicit about visual symptoms. Blurring, spots and flashes, described as scintillating scotomata, can occur during therapy, their incidence rises with total dose and length of treatment, and they are usually reversible, though prolonged disturbances have been reported, including after the drug was stopped.
Other effects reported in the male literature are the ones you would expect from changing estrogen signalling: hot flushes, headaches, mood changes, and in some men breast tenderness. Because clomiphene blocks estrogen receptors rather than lowering estrogen, circulating estradiol can rise while its effects are partly blocked, which is why some men feel worse before blood work looks better.
Blood work and monitoring
| Marker | Why it matters | When |
|---|---|---|
| Total testosterone, morning | The main endpoint of the whole exercise | Baseline, week 4, end of course |
| Luteinizing hormone and follicle stimulating hormone | Confirms the drug is acting on the axis | Baseline and week 4 |
| Estradiol | Rises as testosterone aromatises, drives side effects | Baseline and week 4 |
| SHBG and free testosterone | Explains why total testosterone can look fine while free is low | Baseline and end |
| Semen analysis, if fertility is the goal | The outcome that actually matters for conception | Baseline and after 3 months |
| Vision check | Documented label risk, dose dependent | Immediately if symptoms appear |
Example structure, not a recommendation
The table below is a common shape for a run of this kind, written out so the timing and the checkpoints are visible. It is not advice, not a protocol to copy, and not a substitute for a doctor who has seen your blood work.
| Stage | What people typically do | What to check |
|---|---|---|
| Days 1 to 14 | Clomiphene 25 mg daily or 50 mg every other day | Only after the androgen has cleared |
| Day 14 | Blood work | LH, FSH, total testosterone, estradiol |
| Days 15 to 28 | Continue at the same dose | Judge by numbers, not by feel |
| Week 6 | Repeat panel | Decide whether to stop or extend |
Frequently Asked Questions
Where this fits on this site
Clomid belongs to the same recovery toolkit as tamoxifen and hCG, which sit in the cycle support category. If you are still choosing a cycle rather than recovering from one, the oral steroids category and the guide to what anabolic steroids are cover the basics, and the Anavar article explains the suppression side from the other direction.
- PubChem compound summary for clomiphene, CID 2800: molecular formula C26H28ClNO, molecular weight 406.0
- DailyMed label, clomiphene citrate tablets 50 mg: indications, dosing, and the visual symptom warning that increases with dose and duration
- Clomiphene citrate versus testosterone replacement therapy in male hypogonadism: systematic review and meta-analysis, European Journal of Clinical Pharmacology, 2026. PMID 42435198
- Post-cycle therapy after androgen abuse: a narrative review of mechanisms, evidence, and clinical perspectives, Endocrine Connections, 2026. PMID 42644333
Medical disclaimer. This article is informational and does not replace advice from a licensed physician. Clomiphene for male use is off label, and the evidence behind it is limited. Blood work and medical supervision are the minimum.